"QSAR: dead or alive?": Journal of Computer-Aided Molecular Design

SpringerLink - Journal Article: "QSAR: dead or alive?"

Another article analysing decline of use of QSAR in drug design. It happens that the previous similar article* also came from Bristol-Myers Squibb.


*http://pubs.acs.org/cgi-bin/abstract.cgi/jcisd8/asap/abs/ci700332k.html

Growth of the Asian health-care market: global implications for the pharmaceutical industry : Nature Reviews Drug Discovery

Growth of the Asian health-care market: global implications for the pharmaceutical industry : Nature Reviews Drug Discovery

The stats says that India is one of the worse in Asia in health care.
Check the graphs at nature drug discovery reviews..

Re-engineered Gleevec reduces heart risks

Re-engineered Gleevec reduces heart risks

Scientist at Rice-M. D. Anderson came up with a successful example of rational computer based drug design; yet another one in recent CADD approaches.

List of World’s Fastest Supercomputers

30th Edition of TOP500 List of World’s Fastest Supercomputers Released, Big Turnover Among the Top 10 Systems | TOP500 Supercomputing Sites:

Finally India into the top 10 of supercomputing!!
Check the news...

"For the first time ever, India placed a system in the Top 10. The Computational Research Laboratories, a wholly owned subsidiary of Tata Sons Ltd. in Pune, India, installed a Hewlett-Packard Cluster Platform 3000 BL460c system. They integrated this system with their own innovative routing technology and achieved 117.9 TFlop/s performance."

Trends in the globalization of clinical trials : Article : Nature Reviews Drug Discovery

Trends in the globalization of clinical trials : Article : Nature Reviews Drug Discovery

It's evident that clinical trials are among the top latest happening things in Indian pharmaceutical industry. In this nature article, India with 20% growth in clinical trials is ranked (16th) ahead of China (25th). But wait, China shows an amazing growth of 47%, the most by any countries. Keep watching, something is really happening around....

Patenting the drug targets: New horizon and new social/monetary impacts

Reach-through claims for drug target patents: Rx for pharmaceutical policy :

When a major chunk of scientific community debate for a free world (GNU), here comes a new development; patent the targets and earn money through the drugs acting on it.. Who'll finally pay for it? The unfortunate patients..

However this will be a motivating news to the biologist/pharmacologist who work hard to find novel targets but who are usually least benefited in monetary terms. It is crucial to make a fool-proof patent law in this regard. Otherwise, it'll hinder not only the scientific freedom but also treatment availability to the poor suffering patients.

The Trouble with QSAR (or How I Learned To Stop Worrying and Embrace Fallacy)

The Trouble with QSAR (or How I Learned To Stop Worrying and Embrace Fallacy)

Interesting article!













The picture provided is hilarious :)

(*Image from ACS J. Chem. Inf. Model.)